FCG Investment Co Has $1.78 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

FCG Investment Co raised its position in United Therapeutics Co. (NASDAQ:UTHR) by 10.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,040 shares of the biotechnology company’s stock after buying an additional 472 shares during the quarter. United Therapeutics accounts for 1.1% of FCG Investment Co’s holdings, making the stock its 26th biggest holding. FCG Investment Co’s holdings in United Therapeutics were worth $1,778,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. USA Financial Formulas bought a new stake in shares of United Therapeutics in the third quarter valued at approximately $33,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics during the 3rd quarter worth $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics during the 3rd quarter worth $82,000. MassMutual Private Wealth & Trust FSB increased its position in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the period. Finally, Values First Advisors Inc. acquired a new position in United Therapeutics in the third quarter valued at about $90,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent analyst reports. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. TD Cowen upped their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, LADENBURG THALM/SH SH raised their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $371.89 on Friday. The firm has a market cap of $16.60 billion, a PE ratio of 16.33, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm’s fifty day moving average is $365.04 and its 200-day moving average is $355.24.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.38 earnings per share. Sell-side analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 7,800 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the sale, the chief financial officer now owns 6,978 shares of the company’s stock, valued at $2,442,300. This trade represents a 52.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $940,373.07. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 146,848 shares of company stock worth $55,165,099. 11.90% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.